Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs

被引:35
作者
Chen, C
Casale, EJ
Duncan, B
Calverhouse, EH
Gilman, J
机构
[1] Glaxo Wellcome Inc, Div Clin Pharmacol, Res Triangle Pk, NC 27709 USA
[2] Glaxo Wellcome Inc, Div Cent Nervous Syst Clin Res, Res Triangle Pk, NC 27709 USA
[3] Glaxo Wellcome Inc, Div Clin Pharmacol Data Sci, Res Triangle Pk, NC 27709 USA
[4] Glaxo Wellcome Inc, Div Bioanal & Drug Metab, Res Triangle Pk, NC 27709 USA
[5] Miami Childrens Hosp, Dept Neurosci, Miami, FL USA
来源
PHARMACOTHERAPY | 1999年 / 19卷 / 04期
关键词
D O I
10.1592/phco.19.6.437.31052
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We evaluated the pharmacokinetics of lamotrigine in 12 children with epilepsy who were receiving no other antiepileptic drugs. Each patient received a single oral dose of lamotrigine 2 mg/kg. Plasma concentrations of the drug were measured up to 48 hours after dosing. Pharmacokinetic parameters were calculated using concompartmental methods. After rapid absorption, the lamotrigine concentration declined monoexponentially. Oral clearance was 0.64 +/- 0.26 ml/min/kg. The apparent volume of distribution was 1.50 +/- 0.51 L/kg. Weight-normalized clearance and volume were higher in children than in adults. The mean half-life was 32 hours, similar to that in adults. Should similar plasma lamotrigine: concentrations in adults and children be desirable, children will likely require higher weight-normalized doses at the same dosing frequency.
引用
收藏
页码:437 / 441
页数:5
相关论文
共 33 条
  • [1] Bidirectional interaction of valproate and lamotrigine in healthy subjects
    Anderson, GD
    Yau, MK
    Gidal, BE
    Harris, SJ
    Levy, RH
    Lai, AA
    Wolf, KB
    Wargin, WA
    Dren, AT
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) : 145 - 156
  • [2] LAMOTRIGINE FOR THE TREATMENT OF EPILEPSY IN CHILDHOOD
    BESAG, FMC
    WALLACE, SJ
    DULAC, O
    ALVING, J
    SPENCER, SC
    HOSKING, G
    [J]. JOURNAL OF PEDIATRICS, 1995, 127 (06) : 991 - 997
  • [3] DOUBLE-BLIND COMPARISON OF LAMOTRIGINE AND CARBAMAZEPINE IN NEWLY-DIAGNOSED EPILEPSY
    BRODIE, MJ
    RICHENS, A
    YUEN, AWC
    [J]. LANCET, 1995, 345 (8948): : 476 - 479
  • [4] CHANG G, 1997, EPILEPSIA S3, V38, P32
  • [5] Chang Gregory, 1997, Neurology, V48, pA335
  • [6] LAMOTRIGINE, A NEW ANTICONVULSANT - PHARMACOKINETICS IN NORMAL HUMANS
    COHEN, AF
    LAND, GS
    BREIMER, DD
    YUEN, WC
    WINTON, C
    PECK, AW
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (05) : 535 - 541
  • [7] Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy
    Eriksson, AS
    Hoppu, K
    Nergardh, A
    Boreus, L
    [J]. EPILEPSIA, 1996, 37 (08) : 769 - 773
  • [8] FRANK LM, 1997, ANN NEUROL, V42, P489
  • [9] GOA KL, 1993, DRUGS, V46, P1
  • [10] Hauser W., 1990, EPILEPSY FREQUENCY C